

# Preclinical assessment of the efficacy and specificity of metastatic neuroblastoma

Nature Communications

12, 511

DOI: [10.1038/s41467-020-20785-x](https://doi.org/10.1038/s41467-020-20785-x)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Hypoxia-inducible CAR expression: An answer to the on-target/off-tumor dilemma?. Cell Reports Medicine, 2021, 2, 100244.	6.5	7
2	Immune Checkpoints in Pediatric Solid Tumors: Targetable Pathways for Advanced Therapeutic Purposes. Cells, 2021, 10, 927.	4.1	8
3	The Role of Sphingolipids in Cancer Immunotherapy. International Journal of Molecular Sciences, 2021, 22, 6492.	4.1	11
4	Strategies to improve the safety profile of CAR-T therapy. Postępy Polskiej Medycyny I Farmacji, 2021, 8, 48-60.	0.0	0
5	Advances in immunotherapeutic targets for childhood cancers: A focus on glypican-2 and B7-H3. , 2021, 223, 107892.		11
7	Ganglioside Composition Distinguishes Anaplastic Ganglioglioma Tumor Tissue from Peritumoral Brain Tissue: Complementary Mass Spectrometry and Thin-Layer Chromatography Evidence. International Journal of Molecular Sciences, 2021, 22, 8844.	4.1	5
8	Effective killing of cells expressing CD276 (B7-H3) by a bispecific T cell engager based on a new fully human antibody. Translational Oncology, 2021, 14, 101232.	3.7	6
9	Multi-input biocomputer gene circuits for therapeutic application. Current Opinion in Systems Biology, 2021, 28, 100371.	2.6	1
10	Molecular Basis and Clinical Features of Neuroblastoma. JMA Journal, 2021, 4, 321-331.	0.8	6
11	Significant Dark Current Suppression in Organic Photodetectors Using Side Chain Fluorination of Conjugated Polymer. Advanced Functional Materials, 2022, 32, 2108026.	14.9	28
12	CAR T Cell Therapy's Potential for Pediatric Brain Tumors. Cancers, 2021, 13, 5445.	3.7	10
13	Targeting Oncogenic Transcriptional Networks in Neuroblastoma: From N-Myc to Epigenetic Drugs. International Journal of Molecular Sciences, 2021, 22, 12883.	4.1	9
14	A Reversible Chemogenetic Switch for Chimeric Antigen Receptor T Cells. Angewandte Chemie - International Edition, 2022, 61, .	13.8	8
15	A Recurring Chemogenetic Switch for Chimeric Antigen Receptor T Cells. Angewandte Chemie, 0, , .	2.0	0
16	Outcome of children with relapsed high-risk neuroblastoma in Japan and analysis of the role of allogeneic hematopoietic stem cell transplantation. Japanese Journal of Clinical Oncology, 2022, 52, 486-492.	1.3	4
17	Synthetic Biology in Chimeric Antigen Receptor T (CAR T) Cell Engineering. ACS Synthetic Biology, 2022, 11, 1-15.	3.8	14
18	Chimeric antigen receptor-engineered adoptive cell therapy for AML: Current status and future perspectives. Immunomedicine, 2022, 2, .	0.7	0
19	Roadmap to affinity-tuned antibodies for enhanced chimeric antigen receptor T cell function and selectivity. Trends in Biotechnology, 2022, 40, 875-890.	9.3	17

#	ARTICLE	IF	CITATIONS
20	Better by design: What to expect from novel CAR-engineered cell therapies?. <i>Biotechnology Advances</i> , 2022, 58, 107917.	11.7	12
21	A Bibliometric and Knowledge-Map Analysis of CAR-T Cells From 2009 to 2021. <i>Frontiers in Immunology</i> , 2022, 13, 840956.	4.8	30
22	The Thermal Dose of Photothermal Therapy Generates Differential Immunogenicity in Human Neuroblastoma Cells. <i>Cancers</i> , 2022, 14, 1447.	3.7	6
23	miR-15a and miR-15b modulate natural killer and CD8+T-cell activation and anti-tumor immune response by targeting PD-L1 in neuroblastoma. <i>Molecular Therapy - Oncolytics</i> , 2022, 25, 308-329.	4.4	12
24	Special Chimeric Antigen Receptor (CAR) Modifications of T Cells: A Review. <i>Frontiers in Oncology</i> , 2022, 12, 832765.	2.8	18
25	<scp>CAR</scp> cell therapy for lung cancer: Potential and perspective. <i>Thoracic Cancer</i> , 2022, 13, 889-899.	1.9	25
26	Preclinical Evaluation of CD64 As a Potential Target For CAR-T-cell Therapy For Acute Myeloid Leukemia. <i>Journal of Immunotherapy</i> , 2022, 45, 67-77.	2.4	6
27	Acoustofluidic-mediated molecular delivery to human T cells with a three-dimensional-printed flow chamber. <i>Journal of the Acoustical Society of America</i> , 2021, 150, 4534-4547.	1.1	5
28	Immunotherapy against Gliomas. , 0, , .		0
29	Sphingolipids and Lymphomas: A Double-Edged Sword. <i>Cancers</i> , 2022, 14, 2051.	3.7	2
30	How CAR T Cells Breathe. <i>Cells</i> , 2022, 11, 1454.	4.1	4
31	Verification of genetic differences and immune cell infiltration subtypes in the neuroblastoma tumour microenvironment during immunotherapy. <i>World Journal of Surgical Oncology</i> , 2022, 20, .	1.9	2
32	Advancing therapy for neuroblastoma. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 515-533.	27.6	97
34	Nanomedicines and cell-based therapies for embryonal tumors of the nervous system. <i>Journal of Controlled Release</i> , 2022, 348, 553-571.	9.9	5
35	AAMP is a binding partner of costimulatory human B7-H3. <i>Neuro-Oncology Advances</i> , 2022, 4, .	0.7	4
36	From Anti-HER-2 to Anti-HER-2-CAR-T Cells: An Evolutionary Immunotherapy Approach for Gastric Cancer. <i>Journal of Inflammation Research</i> , 0, Volume 15, 4061-4085.	3.5	1
37	Upregulation of CCNB2 and Its Perspective Mechanisms in Cerebral Ischemic Stroke and All Subtypes of Lung Cancer: A Comprehensive Study. <i>Frontiers in Integrative Neuroscience</i> , 0, 16, .	2.1	5
38	Revolution of CAR Engineering For Next-Generation Immunotherapy In Solid Tumors. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	7

#	ARTICLE	IF	CITATIONS
39	Immune checkpoint molecules in neuroblastoma: A clinical perspective. <i>Seminars in Cancer Biology</i> , 2022, 86, 247-258.	9.6	8
40	Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	4
41	Current progress in CAR-T cell therapy for tumor treatment (Review). <i>Oncology Letters</i> , 2022, 24, .	1.8	7
42	Radiation enhances the efficacy of EGFR-targeted CAR-T cells against triple-negative breast cancer by activating NF- $\kappa$ B/Icam1 signaling. <i>Molecular Therapy</i> , 2022, 30, 3379-3393.	8.2	21
43	Extracellular vesicle-mediated immunoregulation in cancer. <i>International Journal of Hematology</i> , 0, , .	1.6	3
44	Applying a clinical lens to animal models of CAR-T cell therapies. <i>Molecular Therapy - Methods and Clinical Development</i> , 2022, 27, 17-31.	4.1	18
45	Synthetic Biology Technologies And Genetically Engineering Strategies For Enhanced Cell Therapeutics. <i>Stem Cell Reviews and Reports</i> , 2023, 19, 309-321.	3.8	2
46	Prospective approaches to enhancing CAR T cell therapy for glioblastoma. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	6
47	Fully murine CD105-targeted CAR-T cells provide an immunocompetent model for CAR-T cell biology. <i>Onc Immunology</i> , 2022, 11, .	4.6	1
48	CAR cell design strategies in solid tumors. <i>International Immunopharmacology</i> , 2022, 113, 109345.	3.8	0
49	Hopes on immunotherapy targeting B7-H3 in neuroblastoma. <i>Translational Oncology</i> , 2023, 27, 101580.	3.7	10
50	ERK Inhibitor Ulixertinib Inhibits High-Risk Neuroblastoma Growth In Vitro and In Vivo. <i>Cancers</i> , 2022, 14, 5534.	3.7	3
51	Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. <i>Nature Reviews Clinical Oncology</i> , 2023, 20, 49-62.	27.6	74
52	Immunotherapy approaches for rare pediatric solid tumors: advances and future directions. <i>Current Opinion in Pediatrics</i> , 2023, 35, 63-74.	2.0	0
53	Fibroblasts and macrophages cooperate to create a pro-tumorigenic and immune resistant environment via activation of TGF- $\beta$ /IL-6 pathway in neuroblastoma. <i>Onc Immunology</i> , 2022, 11, .	4.6	9
54	Preclinical optimization of a GPC2-targeting CAR T-cell therapy for neuroblastoma. , 2023, 11, e005881.		3
55	Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors: The Past and the Future. <i>Journal of Immunotherapy and Precision Oncology</i> , 2023, 6, 19-30.	1.4	1
56	Chimeric antigen receptor-modified cells for the treatment of solid tumors: First steps in a thousand-mile march. , 2023, , 97-131.		0

#	ARTICLE	IF	CITATIONS
57	Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment. <i>Experimental Hematology and Oncology</i> , 2023, 12, .	5.0	37
58	Anti-glycan monoclonal antibodies: Basic research and clinical applications. <i>Current Opinion in Chemical Biology</i> , 2023, 74, 102281.	6.1	1
59	Current progress in chimeric antigen receptor-modified T cells for the treatment of metastatic breast cancer. <i>Biomedicine and Pharmacotherapy</i> , 2023, 162, 114648.	5.6	1
61	The immunotherapy advancement targeting malignant blastomas in early childhood. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
62	Novel scFv against Notch Ligand JAG1 Suitable for Development of Cell Therapies toward JAG1-Positive Tumors. <i>Biomolecules</i> , 2023, 13, 459.	4.0	0
63	Visualizing cell-cell communication using synthetic notch activated MRI. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, .	7.1	7
64	Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility. <i>Journal of Translational Medicine</i> , 2023, 21, .	4.4	5
65	Synthetic biology-inspired cell engineering in diagnosis, treatment, and drug development. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	17.1	17
66	A neutrophil mimicking metal-porphyrin-based nanodevice loaded with porcine pancreatic elastase for cancer therapy. <i>Nature Communications</i> , 2023, 14, .	12.8	12
67	Targeting B7-H3 A Novel Strategy for the Design of Anticancer Agents for Extracranial Pediatric Solid Tumors Treatment. <i>Molecules</i> , 2023, 28, 3356.	3.8	4
68	Stalled CARs: Mechanisms of Resistance to CAR T Cell Therapies. <i>Annual Review of Cancer Biology</i> , 2023, 7, 23-42.	4.5	1
69	The Notch signaling pathway: a potential target for cancer immunotherapy. <i>Journal of Hematology and Oncology</i> , 2023, 16, .	17.0	19
70	B7-H3 in Pediatric Tumors: Far beyond Neuroblastoma. <i>Cancers</i> , 2023, 15, 3279.	3.7	3
71	EXPRESS: Novel Strategies for Chimeric Antigen Receptor T-Cell Therapy for Acute Lymphoblastic Leukemia: Moving Beyond CD19. <i>Journal of Investigative Medicine</i> , 0, .	1.6	0
72	Pathophysiological roles and applications of glycosphingolipids in the diagnosis and treatment of cancer diseases. <i>Progress in Lipid Research</i> , 2023, 91, 101241.	11.6	3
73	Updated Clinical Perspectives and Challenges of Chimeric Antigen Receptor-T Cell Therapy in Colorectal Cancer and Invasive Breast Cancer. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2023, 71, .	2.3	1
74	A Retrospective Analysis of the Therapeutic Outcomes of 117 Neuroblastoma Patients Treated at a Single Pediatric Oncology Center in China. <i>Cancer Control</i> , 2023, 30, .	1.8	0
75	Exploring CAR-T Cell Therapy Side Effects: Mechanisms and Management Strategies. <i>Journal of Clinical Medicine</i> , 2023, 12, 6124.	2.4	1

#	ARTICLE	IF	CITATIONS
76	Adoptive cell therapy in paediatric extracranial solid tumours: current approaches and future challenges. <i>European Journal of Cancer</i> , 2023, 194, 113347.	2.8	0
77	The yes-associated protein (YAP) is associated with resistance to anti-GD2 immunotherapy in neuroblastoma through downregulation of <i>ST8SIA1</i> . <i>Oncolmmunology</i> , 2023, 12, .	4.6	1
78	Current status and future prospects of chimeric antigen receptor-T cell therapy in lymphoma research: A bibliometric analysis. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	3.3	0
79	Synthetic transcription factor engineering for cell and gene therapy. <i>Trends in Biotechnology</i> , 2023, , .	9.3	3
80	Neuroblastoma: an ongoing cold front for cancer immunotherapy. , 2023, 11, e007798.		0
81	CAR-T cell therapy: Where are we now, and where are we heading?. <i>Blood Science</i> , 2023, 5, 237-248.	0.9	0
82	New progress in the treatment of diffuse midline glioma with H3K27M alteration. <i>Heliyon</i> , 2024, 10, e24877.	3.2	0
83	CAR designs for solid tumors: overcoming hurdles and paving the way for effective immunotherapy. <i>Biophysics Reports</i> , 2023, 9, 279.	0.8	0
85	CAR T cells redirected to B7-H3 for pediatric solid tumors: Current status and future perspectives. , 2024, 3, 100160.		0